The Signa Magnus MRI device offers a slew rate and gradient amplitude that are reportedly superior to those of 60 or 70 cm bore whole-body MRI systems.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Signa Magnus system, a 3T magnetic resonance imaging (MRI) system for head-only scanning.
Featuring HyperG gradient technology, the Signa Magnus system facilitates faster MRI scanning with performance levels of 300 mT/m and 750 T/m/s, according to GE HealthCare, the manufacturer of the system. In addition to shorter scan times, the company said the neuroimaging system offers advanced diffusion imaging capabilities and a high signal-to-noise ratio (SNR).
GE HealthCare said the head-only emphasis of the newly FDA-cleared Signa Magnus 3T MRI system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms. (Image courtesy of GE HealthCare.)
Noting an asymmetrical design that shifts the gradient isocenter to the patient edge of the coil, GE HealthCare said the head-only emphasis of the system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms.
“We're very excited about the capabilities Signa Magnus provides,” said Kawin Setsompop, Ph.D., an associate professor of radiology at Stanford University. “I plan to leverage the gradient performance to look at microstructures with diffusion imaging, such as axonal diameter. Additionally, using the high slew rate for efficient readout in terms of EPI and spiral to sample k-space faster will help achieve higher resolution with fewer artifacts.”
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.